Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Jan 28, 2025
Distillery Therapeutics

De novo-designed antivenom for snakebite

BioCentury | Nov 16, 2022
Deals

Kriya rolls up Redpin, adds neurology to its gene therapy scope

In second M&A deal this year, Patient Square-backed Kriya adds epilepsy, trigeminal neuralgia programs along with platform in ‘nine-digit’ acquisition
BioCentury | Sep 6, 2022
Distillery Therapeutics

Targeting three thalamic circuits in Parkinson's disease

BioCentury | Jun 6, 2022
Deals

Sale of programs to J&J leaves Yumanity as shell for Kineta reverse merger

Combined company to advance Seattle biotech’s cancer programs as Yumanity’s eight-year history in neurodegeneration comes to a close
BioCentury | Oct 18, 2021
Regulation

New nasal spray option for dry eye as Oyster Point wins FDA nod

Oyster Point’s Tyrvaya offers dosing advantage over artificial tears
BioCentury | Mar 27, 2020
Emerging Company Profile

Redpin debuts chemogenetic platform for neurology, raises $15.5M

Redpin aims to tamp down neuron excitability with its conditionally active ion channels
BioCentury | Mar 5, 2020
Emerging Company Profile

AiCure: harnessing AI to boost adherence

AiCure is applying AI to visual, vocal and behavioral patient data to optimize trial adherence
Items per page:
1 - 10 of 294